Pliant Therapeutics, Inc. Common Stock (PLRX) Stock Price

PLRXStock

$1.11−31.48%52W

Market Cap$68.73M

P/E—

PEG Ratio—

Div yield—

Beta1.29

PLRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-24.53%

Price vs S&P 500 (4W)5.19%

VGM Score46.94

Book Value / Share (Quarterly)$2.67

P/TBV (Annual)2.73x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.60

Price vs S&P 500 (YTD)-21.84%

Net Profit Margin (TTM)-2871.17%

EPS (TTM)$-2.43

10-Day Avg Trading Volume0.47M

EPS Excl Extra (TTM)$-2.43

EPS (Annual)$-2.43

ROI (Annual)-82.42%

Net Profit Margin (5Y Avg)-2573.80%

Cash / Share (Quarterly)$2.76

ROA (Last FY)-66.31%

EBITD / Share (TTM)$-2.55

ROE (5Y Avg)-54.77%

Operating Margin (TTM)-3156.66%

Cash Flow / Share (Annual)$-2.09

P/B Ratio0.40x

P/B Ratio (Quarterly)0.47x

Net Income / Employee (Annual)$-3,047,800

EV / Revenue (TTM)8.82x

ROA (TTM)-52.11%

EPS Incl Extra (Annual)$-2.43

Current Ratio (Annual)12.00x

Quick Ratio (Quarterly)16.70x

3-Month Avg Trading Volume0.50M

52-Week Price Return-31.48%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$8.40

P/S Ratio (Annual)42.13x

Asset Turnover (Annual)0.00x

52-Week High$1.95

Operating Margin (5Y Avg)-2871.54%

EPS Excl Extra (Annual)$-2.43

CapEx CAGR (5Y)-24.55%

Tangible BV CAGR (5Y)147.93%

26-Week Price Return-12.60%

Quick Ratio (Annual)11.79x

13-Week Price Return-11.20%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)16.89x

Enterprise Value$44.38M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-17.99%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-10211.14%

Cash / Share (Annual)$3.11

3-Month Return Std Dev38.43%

Net Income / Employee (TTM)$-3,047,800

ROE (Last FY)-82.42%

EPS Basic Excl Extra (Annual)$-2.43

Receivables Turnover (TTM)1.58x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.43

Receivables Turnover (Annual)1.58x

ROI (TTM)-62.89%

P/S Ratio (TTM)13.23x

Pretax Margin (5Y Avg)-2573.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$6.40

Price vs S&P 500 (52W)-50.04%

Year-to-Date Return-9.02%

5-Day Price Return-2.63%

EPS Normalized (Annual)$-2.43

ROA (5Y Avg)-45.99%

Net Profit Margin (Annual)-10211.14%

Month-to-Date Return6.73%

Cash Flow / Share (TTM)$-2.74

EBITD / Share (Annual)$-2.55

Operating Margin (Annual)-11654.75%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-53.14%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.43

P/TBV (Quarterly)1.70x

P/B Ratio (Annual)0.41x

Pretax Margin (TTM)-2871.17%

Book Value / Share (Annual)$2.95

Price vs S&P 500 (13W)-13.15%

Beta1.29x

Revenue / Share (TTM)$0.00

ROE (TTM)-69.56%

52-Week Low$1.02

vGradeC

mGradeD

vgmGradeC

PLRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.34	-$0.36	-4.43%(-$0.02)
Q1 2026	May 11, 2026	-$0.36	-$0.32	+10.60%(+$0.04)
Q4 2025	Mar 11, 2026	-$0.38	-$0.35	+6.53%(+$0.02)
Q3 2025	Nov 6, 2025	-$0.52	-$0.43	+17.84%(+$0.09)
Q2 2025	Aug 7, 2025	-$0.68	-$0.71	-4.85%(-$0.03)

PLRX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

2.55

2.40

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
PLRXPliant Therapeutics, Inc. Common Stock	C	—	D	$1.11
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Pliant Therapeutics, Inc. Common Stock

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing oral therapies for fibrotic diseases. Its lead candidate, bexotegrast, is a small-molecule treatment in development for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company targets significant unmet needs in fibrosis treatment.